Radiology. 1990 Jul;176(1):155-9.

Re-186(Sn) HEDP for treatment of painful osseous metastases: initial clinical experience in 20 patients with hormone-resistant prostate cancer.

Maxon HR 3rd, Schroder LE, Thomas SR, Hertzberg VS, Deutsch EA, Scher HI, Samaratunga RC, Libson KF, Williams CC, Moulton JS, et al.

Source

Department of Radiology, Eugene L. Saenger Radioisotope Laboratory, University of Cincinnati Medical Center, OH 45267-0577.

Abstract

Rhenium-186(tin) hydroxyethylidene diphosphonate (HEDP) is a new radiopharmaceutical that localizes in areas of osseous metastases in a manner similar to that of standard bone-scanning agents. It also emits beta particles with sufficient energy to be therapeutically useful. A single intravenous injection of about 33 mCi (1,221 MBq) was given to each of 20 elderly patients with advanced skeletal metastases from hormonally resistant prostate cancer. Prompt, significant relief of pain occurred 80% of the time with no significant side effects and only minimal, transient marrow toxicity. Re-186(Sn) HEDP appears to be a useful new agent for the palliation of painful osseous metastases in prostate cancer.

PMID:: 1693784; [PubMed - indexed for MEDLINE]

Publication Types, MeSH Terms, Substances, Grant Support

LinkOut - more resources

Full Text Sources

Other Literature Sources

COS Scholar Universe

Education

New England Research Institutes Inc.

Medical

Molecular Biology Databases

Supplemental Content

Save items

Related citations in PubMed

Rhenium-186(Sn)HEDP for treatment of painful osseous metastases: results of a double-blind crossover comparison with placebo. [J Nucl Med. 1991]
Rhenium-186(Sn)HEDP for treatment of painful osseous metastases: results of a double-blind crossover comparison with placebo.
Maxon HR 3rd, Schroder LE, Hertzberg VS, Thomas SR, Englaro EE, Samaratunga R, Smith H, Moulton JS, Williams CC, Ehrhardt GJ. J Nucl Med. 1991 Oct; 32(10):1877-81.
Review Rhenium-186 hydroxyethylidene diphosphonate for the treatment of painful osseous metastases. [Semin Nucl Med. 1992]
Review Rhenium-186 hydroxyethylidene diphosphonate for the treatment of painful osseous metastases.
Maxon HR 3rd, Thomas SR, Hertzberg VS, Schroder LE, Englaro EE, Samaratunga R, Scher HI, Moulton JS, Deutsch EA, Deutsch KF. Semin Nucl Med. 1992 Jan; 22(1):33-40.
Rhenium-188-HEDP therapy for the palliation of pain due to osseous metastases in lung cancer patients. [Cancer Biother Radiopharm. 2003]
Rhenium-188-HEDP therapy for the palliation of pain due to osseous metastases in lung cancer patients.
Zhang H, Tian M, Li S, Liu J, Tanada S, Endo K. Cancer Biother Radiopharm. 2003 Oct; 18(5):719-26.
Dose escalation study of rhenium-186 hydroxyethylidene diphosphonate in patients with metastatic prostate cancer. [Eur J Nucl Med. 1994]
Dose escalation study of rhenium-186 hydroxyethylidene diphosphonate in patients with metastatic prostate cancer.
de Klerk JM, Zonnenberg BA, van het Schip AD, van Dijk A, Han SH, Quirijnen JM, Blijham GH, van Rijk PP. Eur J Nucl Med. 1994 Oct; 21(10):1114-20.
Review 186Re-HEDP for metastatic bone pain in breast cancer patients. [Eur J Nucl Med Mol Imaging. 2004]
Review 186Re-HEDP for metastatic bone pain in breast cancer patients.
Lam MG, de Klerk JM, van Rijk PP. Eur J Nucl Med Mol Imaging. 2004 Jun; 31 Suppl 1:S162-70. Epub 2004 Apr 29.

See reviews... See all...

Cited by 4 PubMed Central articles

Therapeutic efficiency of rhenium-188-HEDP in human prostate cancer skeletal metastases. [Br J Cancer. 2003]
Therapeutic efficiency of rhenium-188-HEDP in human prostate cancer skeletal metastases.
Liepe K, Kropp J, Runge R, Kotzerke J. Br J Cancer. 2003 Aug 18; 89(4):625-9.
High activity Rhenium-186 HEDP with autologous peripheral blood stem cell rescue: a phase I study in progressive hormone refractory prostate cancer metastatic to bone. [Br J Cancer. 2002]
High activity Rhenium-186 HEDP with autologous peripheral blood stem cell rescue: a phase I study in progressive hormone refractory prostate cancer metastatic to bone.
O'Sullivan JM, McCready VR, Flux G, Norman AR, Buffa FM, Chittenden S, Guy M, Pomeroy K, Cook G, Gadd J, et al. Br J Cancer. 2002 Jun 5; 86(11):1715-20.
Re-HEDP : pharmacokinetic characterization, clinical and dosimetric evaluation in osseous metastatic patients with two levels of radiopharmaceutical dose. [BMC Nucl Med. 2001]
Re-HEDP : pharmacokinetic characterization, clinical and dosimetric evaluation in osseous metastatic patients with two levels of radiopharmaceutical dose.
Savio E, Gaudiano J, Robles AM, Balter H, Paolino A, López A, Hermida JC, De Marco E, Martinez G, Osinaga E, et al. BMC Nucl Med. 2001; 1(1):2.

See all...

Related information

Related Citations
Calculated set of PubMed citations closely related to the selected article(s) retrieved using a word weight algorithm. Related articles are displayed in ranked order from most to least relevant, with the “linked from” citation displayed first.
Compound (MeSH Keyword)
PubChem chemical compound records that are classified under the same Medical Subject Headings (MeSH) controlled vocabulary as the current articles.
Substance (MeSH Keyword)
PubChem chemical substance (submitted) records that are classified under the same Medical Subject Headings (MeSH) controlled vocabulary as the current articles.
Cited in PMC
Full-text articles in the PubMed Central Database that cite the current articles.
Cited in Books
NCBI Bookshelf books that cite the current articles.

Recent activity

Clear Turn Off Turn On

Re-186(Sn) HEDP for treatment of painful osseous metastases: initial clinical ex...
Re-186(Sn) HEDP for treatment of painful osseous metastases: initial clinical experience in 20 patients with hormone-resistant prostate cancer.
Radiology. 1990 Jul ;176(1):155-9.

PubMed
[Sentinel lymph node biopsy for in situ carcinoma of the breast. Experience at t...
[Sentinel lymph node biopsy for in situ carcinoma of the breast. Experience at the Bács-Kiskun County Hospital and review of the literature].
Magy Seb. 2006 Jun ;59(3):164-72.

PubMed
Murine and human b locus pigmentation genes encode a glycoprotein (gp75) with ca...
Murine and human b locus pigmentation genes encode a glycoprotein (gp75) with catalase activity.
Proc Natl Acad Sci U S A. 1990 Jun ;87(12):4809-13.

PubMed
Diagnostic testing of genetic disorders: limiting the scope of patent claims thr...
Diagnostic testing of genetic disorders: limiting the scope of patent claims through disclosure requirements.
J Law Med. 2006 Aug ;14(1):110-26.

PubMed
Osteopontin--a possible anchor of osteoclasts to bone.
Osteopontin--a possible anchor of osteoclasts to bone.
Proc Natl Acad Sci U S A. 1990 Jun ;87(12):4473-5.

PubMed

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

PubMed

Result Filters

Display Settings:

Send to:

Re-186(Sn) HEDP for treatment of painful osseous metastases: initial clinical experience in 20 patients with hormone-resistant prostate cancer.

Source

Abstract

Publication Types, MeSH Terms, Substances, Grant Support

Publication Types

MeSH Terms

Substances

Grant Support

LinkOut - more resources

Full Text Sources

Other Literature Sources

Education

Medical

Molecular Biology Databases

Supplemental Content

Save items

Related citations in PubMed

Cited by 4 PubMed Central articles

Related information

Recent activity

Simple NCBI Directory

Getting Started

Resources

Popular

Featured

NCBI Information